| Literature DB >> 27476486 |
Dipamoy Datta1, Md Aftabuddin2, Dinesh Kumar Gupta3, Sanghamitra Raha1, Prosenjit Sen4.
Abstract
Human prostate cancer is a complex heterogeneous disease that mainly affects elder male population of the western world with a high rate of mortality. Acquisitions of diverse sets of hallmark capabilities along with an aberrant functioning of androgen receptor signaling are the central driving forces behind prostatic tumorigenesis and its transition into metastatic castration resistant disease. These hallmark capabilities arise due to an intense orchestration of several crucial factors, including deregulation of vital cell physiological processes, inactivation of tumor suppressive activity and disruption of prostate gland specific cellular homeostasis. The molecular complexity and redundancy of oncoproteins signaling in prostate cancer demands for concurrent inhibition of multiple hallmark associated pathways. By an extensive manual curation of the published biomedical literature, we have developed Human Prostate Cancer Hallmarks Map (HPCHM), an onco-functional atlas of human prostate cancer associated signaling and events. It explores molecular architecture of prostate cancer signaling at various levels, namely key protein components, molecular connectivity map, oncogenic signaling pathway map, pathway based functional connectivity map etc. Here, we briefly represent the systems level understanding of the molecular mechanisms associated with prostate tumorigenesis by considering each and individual molecular and cell biological events of this disease process.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27476486 PMCID: PMC4967902 DOI: 10.1038/srep30691
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Human Prostate Cancer Hallmarks Map- A Hypothesis Driven Project.
(a) Prostate cancer at a glance- represents some basic facts around current prostate cancer treatment approach, its limitations and its associated post therapeutic complications. (b) Achilles’ heel in cancer- depicts three important factors and their underlying features that most fundamentally challenges and dampens current molecularly targeted therapies in cancer. (c) ‘Clausewitzian Dictum’ in cancer biology- Here we propose for a multi target strategy, ‘Clausewitzian Dictum’ that essentially calls for a three level targeting- attack at the network level, attack at the cancer hallmark level, and for functional modular level. On the other hand, these three factors-cancer protein interactome network, cancer hallmark functional ability and its modular signaling network architecture together comprises the Achilles’ heel in cancer. (d) Our Bottom Up Approach- Adaptor protein comprises our initial seed protein. Binary protein interaction database [Human Protein Reference Database (HRPD)] provides information for adaptor protein and its physical interacting partner. For accessing the role of adaptor protein and its binary interacting partner in the context of prostate cancer, we manually curated the literature for each of adaptor protein and its corresponding interacting partner. Based on these information, we reconstruct adaptor centric molecular interactome in human prostate cancer. For gaining a functional organizational view, we then extracts various oncogenic signaling pathways maps, subnetworks and modules associated with diverse cell biological events and hallmark related phenomenon with other literature mined information’s (detailed in the material and methods section). (e) Human Prostate Cancer Hallmarks Map Features- It provides a comprehensive resource for revealing molecular architecture of human prostate cancer at four specific levels namely, prostate cancer hallmark & its underlying feature based phenomenon, prostate cancer hallmark based and cell biological function based molecular connectivity map, hallmark based and its underlying events related oncogenic signaling pathway map, hallmark and inter hallmark related pathway based functional connectivity map.
Content of Human Prostate Cancer Hallmarks Map.
| Cancer Hallmarks/ Cell Bilogical Features | Molecular Components | Network Statistics | Oncogenic Signaling Pathway | Pathway based Functional Connectivity Map | |
|---|---|---|---|---|---|
| Classical Cancer Hallmarks | Proteins | Nodes | Edges | Proteins | No of Connectivity Maps |
| Evasion of growth suppression | 62 | 88 | 110 | 90 | 14 |
| Sustaning proliferative signaling | 100 | 163 | 468 | 91 | 21 |
| Tumour promoting inflammation | 12 | 23 | 63 | 29 | 16 |
| Genome instability & Mutation | 56 | 56 | 125 | — | 19 |
| Cell death resistance | 36 | 92 | 90 | 89 | 13 |
| Angiogenesis | 23 | 43 | 41 | 42 | 15 |
| Metastasis | 106 | 157 | 427 | 101 | 14 |
| Metabolic reprogramming | 23 | — | — | 78 | — |
| Avoidance of Immune Destruction | 22 | — | — | 43 | — |
| Replicative Immortalization | 29 | — | — | 38 | — |
| Tumour Microenvironment | 30 | — | — | 74 | — |
| Prostate Cancer Unique Hallmarks | |||||
| AR mediated signaling | 17 | 116 | 115 | 58 | — |
| Androgen Independence | 29 | — | — | 143 | — |
| Castration Resistance | 49 | — | — | 130 | — |
| Cell Bilogical Features | |||||
| Cell Cycle | 27 | — | — | 75 | — |
| Tumour Suppression | 39 | — | — | 93 | — |
| Cell Growth | 59 | 95 | 103 | 90 | 18 |
| Cell Survival | 35 | 91 | 95 | 91 | 9 |
| Cell Proliferation | 56 | 91 | 101 | 90 | 15 |
| Chemoresistance | 7 | 37 | 32 | 37 | — |
| Cell Migration | 46 | 82 | 93 | 82 | 18 |
| Cell Motility | 33 | 68 | 89 | 66 | 18 |
| Cell Adhesion | 21 | 41 | 42 | 40 | 4 |
| Cell Invasion | 53 | 71 | 73 | 71 | 16 |
| Bone Metastasis | 13 | 13 | 24 | — | 13 |
| Epithelial Mesenchymal Transition (EMT) | 22 | 39 | 34 | 38 | — |
Node represents number of proteins and edge indicates number of binary (physical) interactions between the proteins present in network.
Molecular components of Human Prostate Cancer Hallmarks Map.
| Cancer Hallmarks/Cell Bilogical Features | Total Proteins(Intrinsic Components) | Adaptors | Receptors | Kinases | Enzymes | Transcription Factors & Regulators | Other Signaling Proteins | Last Update |
|---|---|---|---|---|---|---|---|---|
| Classical Cancer Hallmarks | ||||||||
| Evasion of growth suppression | 62 | 9 | 8 | 4 | 4 | 16 | 21 | 2015 |
| Sustaning proliferative signaling | 100 | 23 | 25 | 18 | 6 | 14 | 14 | 2015 |
| Tumour promoting inflammation | 12 | 2 | 5 | — | — | 3 | 2 | 2015 |
| Genome instability & Mutation | 56 | 16 | 14 | 5 | — | 8 | 13 | 2015 |
| Cell death resistance | 36 | 14 | 8 | 5 | 2 | 4 | 3 | 2015 |
| Angiogenesis | 23 | 1 | 8 | 6 | — | 4 | 4 | 2015 |
| Metastasis | 106 | 18 | 20 | 14 | 5 | 22 | 27 | 2015 |
| Metabolic reprogramming | 23 | 4 | 2 | 3 | 3 | 2 | 9 | 2015 |
| Avoidance of Immune Destruction | 22 | — | 4 | — | 2 | 3 | 13 | 2015 |
| Replicative Immortalization | 29 | 1 | 4 | 3 | 3 | 9 | 9 | 2015 |
| Tumour Microenvironment | 30 | 1 | 8 | 1 | 5 | 3 | 12 | 2015 |
| Prostate Cancer Unique Hallmarks | ||||||||
| AR mediated signaling | 17 | 1 | 4 | 4 | 1 | 5 | 2 | 2015 |
| Androgen Independence | 29 | 3 | 7 | 3 | 3 | 4 | 9 | 2015 |
| Castration Resistance | 49 | 5 | 7 | 9 | 5 | 9 | 14 | 2015 |
| Cell Biological Features | ||||||||
| Cell Cycle | 27 | 5 | 2 | 3 | 1 | 4 | 12 | 2015 |
| Tumour Suppression | 39 | 5 | 5 | 1 | 3 | 12 | 13 | 2015 |
| Cell Growth | 59 | 10 | 17 | 14 | 3 | 7 | 8 | 2015 |
| Cell Survival | 35 | 9 | 11 | 7 | 1 | 3 | 4 | 2015 |
| Cell Proliferation | 56 | 12 | 11 | 6 | 3 | 8 | 16 | 2015 |
| Chemoresistance | 7 | 3 | 1 | 1 | — | 1 | 1 | 2015 |
| Cell Migration | 46 | 10 | 12 | 5 | 1 | 10 | 8 | 2015 |
| Cell Motility | 33 | 8 | 5 | 7 | 1 | 4 | 8 | 2015 |
| Cell Adhesion | 21 | 5 | 6 | 1 | — | 1 | 8 | 2015 |
| Cell Invasion | 53 | 10 | 11 | 7 | 2 | 10 | 13 | 2015 |
| Epithelial Mesenchymal Transition (EMT) | 22 | — | 5 | 2 | 2 | 7 | 6 | 2015 |
| Bone Metastasis | 13 | — | 7 | 2 | — | 2 | 2 | 2015 |
Oncogenic signaling pathway map statistics
| Cancer Hallmarks/Cell Bilogical Features | Total Proteins | Adaptors | Receptors | Transcription Factors & Regulators | OtherSignaling Proteins | Oncogenes | TumourSuppressor Proteins | Modulators | Gene expressions | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Classical Cancer Hallmarks | ||||||||||
| Evasion of growth suppression | 90 | 10 | 14 | — | 66 | 14 | 19 | 6 | — | |
| Sustaning proliferative signaling | 91 | 6 | 8 | 12 | 65 | 17 | 3 | 14 | 30 | |
| Tumour promoting inflammation | 29 | 3 | 5 | 3 | 18 | 5 | 2 | 3 | 1 | |
| Cell death resistance | 89 | 13 | 11 | 11 | 54 | 15 | 7 | 5 | 16 | |
| Angiogenesis | 42 | 4 | 10 | 5 | 23 | 7 | 3 | 2 | 7 | |
| Metastasis | 101 | 11 | 24 | 17 | 49 | 16 | 5 | 5 | 27 | |
| Metabolic reprogramming | 78 | 3 | 16 | 5 | 54 | 15 | 8 | 17 | 12 | |
| Avoidance of Immune Destruction | 43 | 1 | 9 | 3 | 30 | 6 | 1 | 2 | 17 | |
| Replicative Immortalization | 38 | 2 | 3 | 9 | 24 | 7 | 7 | 7 | 3 | |
| Tumour Microenvironment | 73 | 3 | 19 | 9 | 42 | 9 | 1 | 6 | 12 | |
| Prostate Cancer Unique Hallmarks | ||||||||||
| AR mediated signaling | 58 | 6 | 4 | 7 | 41 | 9 | 2 | 7 | 16 | |
| Androgen Independence | 143 | 8 | 18 | 27 | 90 | 25 | 10 | 23 | 22 | |
| Castration Resistance | 130 | 7 | 12 | 21 | 90 | 18 | 4 | 11 | 29 | 63 |
| Cell Biological Features | ||||||||||
| Cell Cycle | 75 | 4 | 9 | 14 | 48 | 14 | 6 | 2 | 13 | |
| Tumour Suppression | 93 | 4 | 9 | 0 | 80 | 14 | 56 | 3 | 0 | |
| Cell Growth | 90 | 8 | 12 | 11 | 59 | 22 | 3 | 6 | 21 | |
| Cell Survival | 91 | 5 | 20 | 12 | 54 | 19 | 4 | 6 | 23 | |
| Cell Proliferation | 90 | 10 | 15 | 9 | 56 | 17 | 7 | 5 | 18 | |
| Chemoresistance | 37 | 2 | 9 | 7 | 19 | 14 | 3 | 4 | 12 | |
| Cell Migration | 82 | 13 | 18 | 11 | 40 | 14 | 7 | 5 | 12 | |
| Cell Motility | 66 | 9 | 16 | 6 | 35 | 18 | 3 | 3 | 12 | |
| Cell Adhesion | 40 | 10 | 10 | 2 | 18 | 7 | 2 | 6 | 6 | |
| Cell Invasion | 71 | 11 | 17 | 11 | 32 | 19 | 7 | 9 | 15 | |
| Epithelial Mesenchymal Transition (EMT) | 38 | 3 | 5 | 9 | 21 | 11 | 2 | 8 | 7 | |
Hallmarks related oncogenic functional connectivity map (pathway based) statistics.
| Name of Pathway | Network statistics | ||||||
|---|---|---|---|---|---|---|---|
| EVGS | SPS | TPI | GIM | ANG | MET | CDR | |
| Actin cytoskeletal regulation | N-11, E-14 | ||||||
| Adherens junction | N-4, E-5 | N-12, E-19 | N-4, E-2 | N-13, E-21 | |||
| Alpha6 Beta4 mediated signaling | N-15, E-32 | N-8, E-12 | N-4, E-4 | ||||
| Androgen receptor mediated signaling | N-4, E-5 | N-16, E-35 | N-11, E-19 | N-6, E-9 | N-13, E-30 | ||
| AP-1 transcription factor associated signaling | N-10, E-15 | N-21, E-55 | |||||
| ATM dependent DNA damage response | N-3, E-2 | ||||||
| Bladder cancer associated pathogenesis | N-10, E-9 | ||||||
| CDC42 mediated signaling | N-21, E-55 | ||||||
| Chronic myeloid leukemia pathogenesis | N-6, E-5 | N-12, E-14 | N-7, E-8 | N-15, E-22 | N-9, E-11 | ||
| Class I PI3K mediated signaling | N-48, E-110 | N-13, E-20 | N-20, E-27 | ||||
| Colorectal cancer pathogenesis | N-5, E-7 | N-17, E-29 | N-8, E-13 | N-12, E-18 | N-4, E-3 | N-10, E-14 | |
| DNA damage response | N-14, E-17 | N-9, E-12 | |||||
| EGFR mediated signaling | N-19, E-44 | N-12, E-14 | |||||
| Endometrial cancer associated pathogenesis | N-9, E-8 | ||||||
| ERBB mediated signaling | N-13, E-21 | N-9, E-16 | N-4, E-4 | ||||
| Focal Adhesion | N-16, E-32 | N-10, E-20 | N-7, E-7 | N-14, E-27 | N-5, E-6 | ||
| Glioma associated pathogenesis | N-9, E-9 | N-8, E-12 | N-14, E-27 | N-6, E-5 | N-14, E-19 | N-6, E-7 | |
| IGF1 mediated signaling | N-46, E-134 | ||||||
| IFN-gamma signaling | N-26, E-63 | ||||||
| IL-2 mediated signaling | N-15, E-24 | N-9, E-11 | |||||
| IL-3 mediated signaling | N-19, E-40 | ||||||
| IL-5 mediated signaling | N-14, E-23 | ||||||
| IL-6 mediated signaling | N-17, E-39 | N-7, E-7 | |||||
| IL-7 mediated signaling | N-7, E-7 | ||||||
| IL-11 mediated signaling | N-8, E-9 | ||||||
| Insulin mediated signaling | N-48, E-110 | N-20, E-27 | |||||
| Integrin-linked kinase associated signaling | N-21, E-55 | ||||||
| JAK-STAT signaling | N-6, E-5 | ||||||
| Kit receptor associated signaling | N-5, E-4 | N-4, E-3 | |||||
| Leptin signaling | N-11, E-25 | N-5, E-5 | |||||
| MAPK signaling | N-5, E-3 | N-13, E-15 | N-4, E-3 | ||||
| Melanoma pathogenesis | N-9, E-8 | N-13, E-15 | N-7, E-5 | ||||
| Microtubule cytoskeletal regulation | N-5, E-6 | ||||||
| Neurotrophin signaling | N-4, E-3 | ||||||
| Non small lung cancer associated pathogenesis | N-10, E-11 | ||||||
| Oncostatin M signaling | N-12, E-19 | N-10, E-9 | N-4, E-3 | ||||
| Pancreatic cancer pathogenesis | N-5, E-7 | N-11, E-13 | N-8, E-10 | N-13, E-13 | N-6, E-5 | N-20, E-30 | N-7, E-8 |
| PAR1 mediated thrombin signaling | N-10, E-15 | ||||||
| PDGFR-beta associated signaling | N-23, E-63 | N-13, E-20 | |||||
| Prolactin signaling | N-10, E-17 | N-11, E-12 | N-14, E-21 | ||||
| Senescence & autophagy associated signaling | N-5, E-3 | N-10, E-11 | N-5, E-4 | ||||
| TGF beta associated signaling | N-4, E-5 | N-20, E-42 | N-11, E-21 | N-13, E-19 | |||
| TRAIL signaling | N-23, E-29 | ||||||
| VEGF signaling | N-4, E-4 | ||||||
Abbreviations: EVGS-Evasion of growth suppression, SPS-sustaining proliferative signaling, TPI-Tumor promoting inflammation, GIM-Genomic instability & mutation, ANG-Angiogenesis, MET-Metastasis, CDR-Cell death resistance, N- Node, number of protein present in the corresponding network, E-Edge, number of binary (physical) interactions between the proteins present in the corresponding network
Cell biological feature related oncogenic functional connectivity map (pathway based) statistics.
| Name of Pathway | Network statistics | |||||||
|---|---|---|---|---|---|---|---|---|
| CPN | CGH | CSV | CMG | CML | CIV | CAH | OVP | |
| Actin cytoskeletal regulation | N-7, E-7 | |||||||
| Adherens junction | N-8, E-9 | N-8, E-12 | N-9, E-10 | N-4, E-3 | N-8, E-13 | |||
| Alpha6 Beta4 mediated signaling | N-11, E-21 | N-6, E-6 | N-7, E-10 | |||||
| Androgen receptor mediated signaling | N-11, E-21 | N-12, E-24 | N-9, E-16 | N-7, E-8 | N-9, E-17 | N-3, E-2 | ||
| ARF6 trafficking event | N-16, E-31 | |||||||
| ATM dependent DNA damage response | N-8, E-9 | N-6, E-5 | ||||||
| Chemokine mediated signaling | N-11, E-18 | N-8, E-6 | N-8, E-8 | |||||
| Chronic myeloid leukemia pathogenesis | N-8, E-8 | N-6, E-5 | ||||||
| Class I PI3K mediated signaling | N-30, E-56 | N-21, E-28 | ||||||
| Colorectal cancer pathogenesis | N-8, E-9 | N-10, E-15 | N-4, E-3 | N-8, E-9 | ||||
| EGFR mediated signaling | N-8, E-7 | N-13, E-28 | N-3, E-2 | N-11, E-15 | ||||
| Estrogen receptor mediated signaling | N-31, E-59 | N-8, E-9 | N-10, E-10 | |||||
| Endometrial cancer associated pathogenesis | N-7, E-7 | |||||||
| ERBB mediated signaling | N-8, E-7 | N-11, E-18 | N-6, E-7 | |||||
| Focal Adhesion | N-9, E-11 | N-14, E-31 | N-8, E-8 | N-8, E-10 | N-9, E-13 | N-8, E-11 | N-4, E-4 | N-7, E-7 |
| Glioma associated pathogenesis | N-7, E-7 | |||||||
| HGF mediated signaling | N-8, E-10 | |||||||
| IGF1 mediated signaling | N-7, E-6 | |||||||
| IFN-gamma signaling | N-17, E-35 | N-10, E-14 | ||||||
| IL-2 mediated signaling | N-4, E-3 | |||||||
| IL-3 mediated signaling | N-11, E-21 | N-6, E-5 | N-9, E-11 | |||||
| IL-5 mediated signaling | N-10, E-15 | N-5, E-4 | ||||||
| IL-6 mediated signaling | N-13, E-27 | N-4, E-3 | N-6, E-6 | |||||
| IL-11 mediated signaling | N-6, E-5 | |||||||
| Insulin mediated signaling | N-6, E-5 | N-8, E-7 | ||||||
| Integrin mediated cell adhesion | N-7, E-10 | |||||||
| Kit receptor associated signaling | N-9, E-18 | N-5, E-4 | ||||||
| Leptin signaling | N-8, E-6 | N-9, E-11 | ||||||
| MAPK signaling | N-7, E-5 | N-6, E-5 | ||||||
| Melanoma pathogenesis | N-7, E-6 | |||||||
| Neurotrophin signaling | N-8, E-7 | N-5, E-5 | ||||||
| Oncostatin M signaling | N-7, E-8 | |||||||
| Pancreatic cancer pathogenesis | N-12, E-13 | N-6, E-5 | N-7, E-5 | N-5, E-3 | ||||
| p75(NTR) mediated signaling | N-8, E-7 | N-7, E-5 | ||||||
| Prolactin signaling | N-12, E-12 | N-10, E-15 | N-3, E-2 | |||||
| TGF beta associated signaling | N-9, E-8 | N-12, E-20 | N-8, E-6 | N-9, E-12 | N-8, E-9 | |||
| TRAIL signaling | N-9, E-9 | |||||||
| VEGF signaling | N-5, E-4 | N-6, E-5 | ||||||
| Wnt signaling | N-10, E-10 | N-8, E-8 | ||||||
| uPAR mediated signaling | N-21, E-28 | |||||||
Abbreviations: CPN-Cell proliferation, CGH-Cell growth, CSV-Cell survival, CMG-Cell migration, CML-Cell motility, CIV-Cell invasion, CAH-Cell adhesion, OVP-Overexpression, N-Node, number of protein present in the corresponding network, E-Edge, number of binary [physical] interactions between the proteins present in the corresponding network.
A summary of inter-hallmark functional connectivity map.
| EVGS | SPS | TPI | GIM | CDR | ANG | MET | |
|---|---|---|---|---|---|---|---|
| 6 | — | 9 | 3 | — | 6 | ||
| 17 | 34 | 17 | 13 | 44 | |||
| 12 | 4 | 7 | 13 | ||||
| 16 | 7 | 23 | |||||
| 19 | 12 | ||||||
| 13 | |||||||
Abbreviations: EVGS-Evasion of growth suppression, SPS-sustaining proliferative signaling, TPI-Tumor promoting inflammation, GIM-Genomic instability & mutation, ANG-Angiogenesis, MET-Metastasis, CDR-Cell death resistance. Number indicates common protein between two corresponding hallmark.
A summary of inter-cell biological feature based functional connectivity map.
| CGH | CSV | CPN | EMT | CMG | CML | CAH | CIV | CMR | BMT | OVP | TSP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 17 | 20 | 17 | 9 | 19 | 8 | 16 | — | 10 | — | ||
| 12 | 16 | — | 29 | 14 | 15 | 17 | 6 | — | — | |||
| 18 | 13 | 32 | 21 | 12 | 15 | 6 | 7 | 5 | ||||
| 19 | 16 | 9 | 15 | 19 | — | — | — | |||||
| 35 | 24 | 23 | 26 | 10 | 9 | — | ||||||
| 20 | — | 35 | 5 | — | — | |||||||
| 23 | 8 | — | — | — | ||||||||
| 39 | 9 | 10 | — | |||||||||
| — | — | — | ||||||||||
| 4 | — | |||||||||||
| — | ||||||||||||
Abbreviations: CGH-Cell growth, CSV-Cell survival, CPN-Cell proliferation, EMT-Epithelial mesenchymal transition, CMG-Cell migration, CML-Cell motility, CAH-Cell adhesion, CIV-Cell invasion, CMR-Chemoresistance, MBT-Bone metastasis, OVP-Overexpression, TSP-Tumour suppressor protein. Number indicates common proteins between two corresponding cell biological features.